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Abstract
Background: Molecular adjuvants are a promising method to enhance virus-specific immune responses and
protect against HIV-1 infection. Immune activation by ligands for receptors such as CD40 can induce dendritic cell
activation and maturation. Here we explore the incorporation of two CD40 mimics, Epstein Barr Virus gene LMP1
or an LMP1-CD40 chimera, into a strain of SIV that was engineered to be limited to a single cycle of infection.
Results: Full length LMP1 or the chimeric protein LMP1-CD40 was cloned into the nef-locus of single-cycle SIV.
Human and Macaque monocyte derived macrophages and DC were infected with these viruses. Infected cells
were analyzed for activation surface markers by flow cytometry. Cells were also analyzed for secretion of pro-
inflammatory cytokines IL-1b, IL-6, IL-8, IL-12p70 and TNF by cytometric bead array.
Conclusions: Overall, single-cycle SIV expressing LMP1 and LMP1-CD40 produced a broad and potent TH1-biased
immune response in human as well as rhesus macaque macrophages and DC when compared with control virus.
Single-cycle SIV-LMP1 also enhanced antigen presentation by lentiviral vector vaccines, suggesting that LMP1-
mediated immune activation may enhance lentiviral vector vaccines against HIV-1.
Background
To develop an effective lentiviral vector vaccine against
HIV-1 infection it may be necessary to focus on enhan-
cing the activation of dendritic cells, and other profes-
sional antigen presenting cells, in order to maximize the
stimulation of virus-specific immune responses. One of
the critical events in the induction of immune response
is the maturation of DCs and macrophages [1]. Matur-
ing DCs and macrophages undergo a rapid burst of
cytokine synthesis and expression of costimulatory
molecules. Dendritic cells then migrate to the T-cell
areas of draining secondary lymphoid organs to prime
naïve T cells and initiate an adaptive immune response
[2]. IL-12p70 is secreted by activated macrophages and
DC and stimulates IFN-g secretion by T lymphocytes
and NK cells [1,3,4]. To improve the efficacy of vac-
cines, we decided to focus on developing single-cycle
SIV vaccines incorporating inducers of antigen present-
ing cell maturation and cytokine secretion, specifically
looking at CD40 stimulation and the role of the viral
protein LMP1.
LMP1 is an integral membrane protein of Epstein Barr
Virus (EBV) with a molecular weight of approximately
63 kDa, consisting of three domains. LMP1 expression
induces many of the changes associated with EBV infec-
tion and activation of primary B cells, including cell
clumping; increased cell surface expression of CD23,
CD39, CD40, CD44; decreased expression of CD10; and
increased expression of the cell adhesion molecules
CD11a (LFA1), CD54 (ICAM1), and CD58 (LFA3) [5-8].
At least four signaling pathways, namely nuclear factor
B( N F - B), c-Jun N-terminal kinase (JNK)-AP-1, p38/
MAPK (mitogen activated protein kinase), and Janus
kinase (JAK)-STAT (signal transducers and activators of
transcription), are implicated in the function of LMP1
[9-12]. Within the C-terminus of LMP1 there are at
least two activating regions referred to as CTAR1 and
CTAR2 (C-terminal activating region). CTAR1 is located
proximal to the membrane (amino acids 186-231) and is
essential for EBV mediated transformation of primary B
cells. CTAR2 (amino acids 351-386) is located at the
extreme C-terminus of LMP1 and is required for long
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Both CTAR1 and CTAR2 can activate NF-Bi n d e p e n -
dently [9]. Aggregation of LMP1 within the plasma
membrane is a crucial prerequisite for signaling. LMP1
aggregation appears to be an intrinsic property of the
transmembrane domain [15]. This signaling is similar to
signaling by the tumor necrosis factor receptor (TNFR)
CD40 [16]. The main difference between LMP1 and the
TNFR family is that LMP1 functions as a constitutively
activated receptor and, therefore, does not rely on the
binding of an extracellular ligand for costimulation [17].
Experiments have also evaluated the chimeric molecule
LMP1-CD40, consisting of the LMP1 transmembrane
domain and the CD40 cytoplasmic tail. These experi-
ments suggest that the LMP1-CD40 chimera is also con-
stitutively active in vitro [18].
In this study, we took advantage of the immunostimu-
latory characteristics of LMP1 and LMP1-CD40 by
incorporating these genes into the genome of pseudo-
typed single-cycle SIV viral particles. These genes are
expected to enhance the immunogenicity of the virus,
thereby stimulating antigen presentation by infected
APC. We evaluated the immunogenicity of SIV-LMP1
and SIV-LMP1-CD40 in vitro using human as well as
macaque monocyte-derived DC and macrophages. Our
data suggest that LMP1 and LMP1-CD40 significantly
enhance the ability of SIV to activate DCs and macro-
phages. SIV-LMP1 also enhances the priming of naive
Gag-specific T cells in vitro. These results are encoura-
ging for the clinical evaluation of LMP1 and LMP1 chi-
meric constructs as a novel class of adjuvant for HIV
vaccines and other immunotherapy strategies.
Results
Preparation of LMP1 and LMP1-CD40
Both LMP1 and LMP1-CD40 chimera genes were con-
structed from PCR fragments, using Raji B cell line
cDNA and human CD40 cDNA as PCR templates. The
resulting proteins are depicted in Figure 1A. The LMP1
N-terminal residues form a domain with six transmem-
brane regions that self-associate in the plane of the
membrane, clustering the cytoplasmic tails of the pro-
tein. The cytoplasmic tail, either from LMP1 or CD40,
contains signaling domains that recruit adapter mole-
cules such as TRAFs to initiate downstream signaling
events. Receptor-ligand interaction is not required to
induce clustering, and as a result both LMP1 and
LMP1-CD40 are constitutively active [18].
Generation of pseudotyped single-cycle SIV expressing
LMP1 or LMP1-CD40
The single-cycle SIV viral construct scSIVmac239FS-
ΔPRΔINEGFP [19] was used as a template to generate
single-cycle SIV virus expressing either LMP1 or LMP1-
CD40 (Figure 1B). After confirming recombinant clones
by sequencing we performed Western blot analysis for
Gag, LMP1, and CD40 following transfection of 293T
cell lysates with SIV viral constructs. Gag (p27) was pre-
sent in all 293T lysates, whereas LMP1 and CD40 pro-
teins were present only for LMP1 and LMP1-CD40
adjuvanted viruses, respectively (Figure 2A). Theoretical
molecular weights of LMP1 (42 kDa) and LMP1-CD40
(28 kDa), were consistent with Western blot values (40
kDa and 30 kDa respectively).
Transduction of human DCS and macrophages with SIV
encoding LMP1 and LMP1-CD40 results in enhanced
activation and maturation
Viruses expressing LMP1, LMP1-CD40, or control GFP
were tested for their ability to activate human DCS
and macrophages. Initially we determined the optimal
infectious dose as MOI of 0.05 and optimal time for
analysis as 4 days post infection (Additional file 1, Fig-
ure S1). Under these conditions, scSIV expressing
LMP1 or LMP1-CD40 induced morphological changes
in DCs and macrophages, including clumping and
elongation of cells within the culture (Figure 2B). Simi-
lar morphological responses were also observed after
treatment with LPS, suggesting that LMP1 and LMP1-
CD40 are inducing activation of cells within the
infected cultures (data not shown). Next we tested the
expression levels of various maturation and activation
surface markers on virus-transduced macrophages and
DCs by flow cytometry. Cells were again evaluated 4
days after infection with scSIV viruses. Transduction
with scSIV-LMP1 resulted in dendritic cell activation
and maturation as measured by significantly increased
levels of CD40, CD80 and CD83 expression, while
scSIV-LMP1-CD40 resulted in significant increased
levels of CD40, CD80 and HLA-DR expression when
compared to scSIV-GFP-transduced cells. (Figure 3A).
These results suggest that the activation signal pro-
vided by LMP1 and LMP1-CD40 is strong enough to
initiate both activation and maturation of DCs. Simi-
larly, there was a significant increase in the expression
of maturation markers CD40 and CD80 on scSIV-
LMP1 transduced macrophages, whereas scSIV-LMP1-
CD40 resulted in an increase in the expression levels
of CD40, CD80 and CD83 (Figure 3B).
scSIV expressing LMP1 or LMP1-CD40 result in increased
secretion of inflammatory cytokines and b-chemokines
from human and macaque DCs and macrophages
We next examined the secretion of various human
inflammatory cytokines by virus-infected DCs or
macrophages. Inflammatory cytokine assays were per-
formed by cytometric bead array (CBA). DCs were
infected with different single-cycle SIV viruses at MOI
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Page 2 of 12of 0.05 and supernatants were collected at various time
intervals. scSIV-LMP1 infection resulted in a signifi-
cant increase in IL-1b,I L - 6 ,I L - 8 ,I L - 1 0 ,I L - 1 2 p 7 0a n d
TNF, while scSIV-LMP1-CD40 infection resulted in
increase in IL-1b,I L - 6 ,I L - 8 ,I L - 1 0a n dT N Fa tv a r i o u s
time points (Figure 4A). Moreover, we could not
detect measurable amounts of IL-12p70 in scSIV-GFP
or scSIV-LMP1-CD40 infected DCs. Additional file 2,
Table S1 summarizes the concentration and p-values
for cytokines secretion from infected human and
macaque DCs and macrophages. Values for scSIV-
LMP1 or scSIV-LMP1-CD40 were compared to scSIV-
GFP. We observed significantly higher secretion of
inflammatory cytokines from macaque DCs and
macrophages upon infection with LMP1 and LMP1-
CD40 adjuvanted scSIV viruses compared to control
virus. In all assays LPS was used as a positive control
and induced high levels of IL-8, IL-6, and TNF from
both dendritic cells and macrophages (data not
shown). These results confirm that LMP1 and LMP1-
CD40 are able to activate DCs and macrophages in
vitro both in humans and non-human primates. These
data show that incorporating LMP1 and LMP1-CD40
into SIV enhances its ability to activate DCs and
macrophages. We also evaluated b-chemokine RNA
expression by real time RT-PCR of macrophages 4
days following infection. Total cellular RNA was iso-
lated, reverse transcribed to cDNA and MIP-1a,M I P -
1b, and RANTES mRNA expression was analyzed by
real time PCR assay. When macrophages were infected
with recombinant scSIV viruses, LMP1 resulted in a
significant increase in MIP-1b and RANTES mRNA
expression, whereas LMP1-CD40 resulted in significant
increase in MIP-1a,M I P - 1 b and RANTES mRNA
expression (Figure 4B). Taken together, these results
suggest that expression of both pro-inflammatory
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Figure 1 Schematic of LMP1 constructs and single cycle SIV genome. (A) Representation of LMP1 functional domains and the LMP1-CD40
chimeric protein. The LMP1 N-terminal transmembrane region enables the formation of clusters in the plasma membrane. This clustering is
essential for LMP1 activity. In the LMP1-CD40 fusion protein, the cell signaling C-terminal region of LMP1 has been replaced and amino acid 190
of LMP1 is linked to the intracellular domain of the CD40 receptor, beginning at amino acid 220 the CD40 protein. (B) Schematic of scSIV viral
genome. The parent vector, expressing GFP from the Nef promoter, was cloned by overlap PCR and inserted into the SIVmac239 FS-ΔPR-ΔINEGFP
vector using unique XbaI and SacII sites. To create immunostimulatory forms of scSIV, LMP1 or LMP1-CD40 were inserted in place of the GFP
gene as shown.
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cycle SIV expressing LMP1 or LMP1-CD40.
SIV-LMP1 infected DCs can enhance antigen-specific
immune responses from autologous T cells
IL-12p70 is an important regulator of IFN-g secretion by
T cells [22]. We therefore investigated whether the con-
ditions that induce IL-12p70 production by scSIV-LMP1
transduced DCs can also increase IFN-g secretion by
autologous T cells following DC stimulation in a 12-day
DC:T cell co-culture assay. DCs were transduced with
scSIV-LMP1, scSIV-LMP1-CD40 or scSIV for 4 days,
washed, and then cultured with autologous T cells for
12 days in the presence of nevirapine and 5 u/ml of IL-
2 (Figure 5A). T cells were then restimulated with an
SIV Gag 15-mer overlapping peptide pool (NIH AIDS
reagent program). IFN-g secreting cells were identified
by ELISPOT analysis. The scSIV-LMP1 and scSIV-
LMP1-CD40 infected DC induced an increased IFN-g T
cell response as compared to the scSIV control (Figure
5B).
Discussion
In the present study, we investigated methods to
develop safe and efficacious SIV vaccines by incorporat-
ing adjuvant genes LMP1 and LMP1-CD40 into the
genome of single cycle SIV. These and similar vaccina-
tion strategies are based on the activation of DCs and
macrophages via CD40 signaling, resulting in an inflam-
matory response that is able to enhance antigen-specific
A
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293TcellLysates
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Figure 2 SIV virus expressing LMP1 or LMP1-CD40 induces morphological changes in DCs and macrophages. (A) Western blot of 293T
cell lysates transfected with SIV expressing LMP1 or LMP1-CD40. Virus expressing GFP served as a negative control. Gag p27 was present in all
lysates. LMP1 and CD40 intracellular domains were present only in cells transfected with LMP1 or LMP1-CD40 viral constructs respectively. Blots
were stained with anti-Gag (upper panels), anti-LMP1 intracellular domain (middle panels), or anti-CD40 intracellular domain (lower panels). (B)
Representative images of human monocyte derived dendritic cells (DCs) or macrophages infected with the various SIV viruses. DCs or
macrophages were infected with the parent single cycle virus SIVmac239 FS-ΔPR-ΔIN (expressing Nef) (10) or a Nef-deleted scSIV expressing GFP,
LMP1, or LMP1-CD40. Only LMP1 or LMP1-CD40 expressing viruses induced elongation of human DCs or macrophages, suggesting the activation
and maturation of cells in the culture.
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Figure 3 Transduction of Human DCs or macrophages with scSIV expressing LMP1 or LMP1-CD40 results in increased levels of
maturation and activation markers. The expression levels of surface markers from three independent experiments are presented as mean
fluorescence intensity (MFI). (A) The expression of surface markers on SIV infected DCs was examined by flow cytometry 4 days after
transduction. Transduction with scSIV-LMP1 resulted in dendritic cell activation and maturation as measured by significantly increased levels of
CD40, CD80 and CD83 expression, while scSIV-LMP1-CD40 resulted in significant increased levels of CD40, CD80 and HLA-DR expression when
compared to scSIV-GFP-transduced cells. (B) The expression level of surface markers on scSIV virus-transduced macrophages was examined 4
days after transduction by flow cytometry from a representative donor. Transduction with scSIV-LMP1 resulted in increased levels of CD40 and
CD80 expression, while scSIV-LMP1-CD40 resulted in increased levels of CD40, CD80 and CD83 expression compared to scSIV-GFP-transduced
macrophages. As the positive control for the maturation and activation, MIMIC cytokine cocktail for DCs and LPS was used for macrophages.
Data were analyzed with the unpaired t test: *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared with the scSIV-GFP infected group.
Gupta et al. Retrovirology 2011, 8:39
http://www.retrovirology.com/content/8/1/39
Page 5 of 12A
m
l
)
t
o
k
i
n
e
s
 
(
p
g
/
m
C
y
t
Time Interval (hrs)
B
MIPͲ1ɲ MIPͲ1ɴ RANTES MIP 1ɲ MIP 1ɴ RANTES
Figure 4 scSIV expressing LMP1 or LMP1-CD40 induces increased secretion of inflammatory cytokines and b-chemokines.H u m a n
inflammatory cytokine quantitation was performed by cytometric bead array (CBA). Cytokine concentrations from three independent
experiments are presented. Data were analyzed with the unpaired t test: *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared with the scSIV-GFP
infected group. MIP-1a, MIP-1b, RANTES mRNA expression was analyzed by real-time RT-PCR assay. (A) DCs were infected with the various SIV
viruses at MOI of 0.05 and supernatants were collected at various time intervals. Virus expressing LMP1 resulted in a significant increase in IL-1b,
IL-6, IL-8, IL-10, IL-12p70 and TNF, while LMP1-CD40 resulted in an increase in IL-1b, IL-6, IL-8, IL-10 and TNF at various time points post infection.
No measurable amounts of IL-12p70 were detected in GFP and LMP1-CD40 groups. (B) Macrophages were infected with different scSIV viruses
for 4 days. Total cellular RNA was isolated, reverse transcribed to cDNA and MIP-1a, MIP-1b, RANTES mRNA expression was analyzed by real-time
PCR assay. Virus expressing LMP1 resulted in significant increase in MIP-1b and RANTES mRNA expression, whereas LMP1-CD40 resulted in
significant increase in MIP-1a, MIP-1b and RANTES mRNA expression. Expression of GAPDH was used for normalization of samples.
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may be especially critical in eliciting CTL responses in
conditions such as AIDS during which the number or
activity of CD4+ T cells is limited. The incorporation of
LMP1 and LMP1-CD40 into scSIV viral particles
resulted in enhanced immunogenicity compared to par-
ent scSIV as evidenced by the induction of TH1c y t o -
kines and both DC and macrophage maturation. The
scSIV viral genome was efficiently recombined with
LMP1, LMP1-CD40 and these proteins were expressed
as confirmed by western blot. As an indication of the
potency of the LMP1 adjuvants, scSIV viruses expressing
LMP1 and LMP1-CD40 induced morphological changes
in DCs and macrophages, including clumping and elon-
gation suggestive of activation of these cells.
The immunogenicity of scSIV incorporating LMP1
and LMP1-CD40 was next evaluated in vitro by measur-
ing the expression levels of cell surface markers trans-
duced DCs and macrophages. The expression levels of
maturation markers CD40, CD80, CD83, CCR7 and
HLA-DR were higher in LMP1 and LMP1-CD40 adju-
vanted scSIV transduced DCs as compared to the GFP
control group. The expression of CD40, CD80, CCR7,
and HLA-DR were similar to positive control cells
matured with cytokines, however the expression level of
CD83 on LMP1 and LMP1-CD40 virus transduced DC
was not as high as that on cytokine cocktail-maturated
DCs (data not shown), suggesting that transduction with
LMP1 and LMP1-CD40 did not induce complete
maturation of the DCs and macrophages in vitro. This
was not unexpected, since we intentionally excluded
other activating stimuli in the culture medium to
increase the sensitivity of the assay. This could be
explained by the fact that the MOI used in the infection
experiments was very low (0.05). This low MOI led to a
low level of transfection, normally 10-20% of cells
exposed to SIV constructs. These results suggest that
the activation signal provided by LMP1 and LMP1-
A
Infect DC with scSIV virus and culture 4 days
B
+
InfectDCwithscSIVvirusandculture4days
+
CocultureDCwithautologousTcellsfor
12daysinthepresenceofnevirapine.
Pf E L I S P O T t i l t i T l l PerformELISPOT,restimulatingTcells
withGag15Ͳmerpeptidepool.
Figure 5 LMP1 induces enhanced T cell responses in a Gag peptide-specific IFN-g ELISPOT assay. (A) Schematic of the experimental
protocol. DCs from an HIV seronegative donor were transduced with scSIV viruses for 4 days, washed, and then incubated with autologous T
cells for 12-days in the presence of nevirapine and IL-2 (5 U/ml) starting on day 3 of the coculture. After 12 days, cultures were restimulated
with a consensus SIVmac239 15-mer Gag peptide pool and IFN-g ELISPOT analysis was performed 24 hours later. (B) DCs infected with parent
scSIV were unable to stimulate anti-SIV T cell responses, while the nef-deleted virus scSIV-GFP induced a modest T cell response. DC infected
with scSIV-LMP1 and LMP1-CD40 significantly enhanced anti-Gag T cell responses (p < 0.001). Results are representative of three independent
experiments using three different donor blood samples.
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enough to induce full maturation. There was also a
modest increase in the expression of maturation mar-
kers such as CD40 and CD83 in LMP1 adjuvanted
scSIV transduced macrophages, whereas LMP1-CD40
adjuvanted scSIV resulted in a marked increase in the
expression levels of CD40, CD80 and CD83 on infected
macrophages. These differences suggest a positive feed-
back whereby CD40 signaling from LMP1-CD40
enhances the expression ofC D 4 0p r o t e i no nt h ec e l l
surface.
Overall, TH1 cytokine secretion was dramatically
enhanced by SIV encoding LMP1, with increased cyto-
kine secretion observed within 12-24 hours post-infec-
tion. This rapid cytokine induction included a modest
level of IL-12p70, suggesting that SIV-LMP1 infected
DCs could potentially enhance SIV-specific T cell
response in vivo. This is balanced with a modest secre-
tion of IL-10 following scSIV-LMP1 infection of DC.
Much greater secretion levels were observed with cyto-
kines IL-1b, IL-6, TNF and especially IL-8. Transduction
with SIV-LMP1 resulted in a 50-fold induction of IL-
12p70 secretion compared to transduction with SIV-
G F P( f r o m~ 1p g / m lt o5 0p g / m la t8 4h o u r s ) .G i v e n
the critical role of IL-12 in the stimulation of IFN-g pro-
duction, proliferation of T cells, and generation of cyto-
toxic T lymphocytes [23], using LMP1 as an adjuvant
should result in increased DC activation and an
enhanced TH1 immune response. This IL-12 induction
is consistent with LMP1 inducing a constitutive CD40-
like signal, a key role in Epstein Barr virus pathogenesis.
Binding of CD40L to its receptor on immature DCs trig-
gers DCs activation and maturation and increases DCs
survival [17]. One of the cytokines upregulated in DCs
activated by CD40L binding is IL-12, a cytokine respon-
sible for polarizing CD4+ T cells to a TH1p h e n o t y p e
[23]. Previous research with DNA vaccines showed that
increasing the activation level of DC through CD40-
CD40L interactions significantly enhances the intensity
of cell mediated immunity and humoral immune
responses [20,21,24-27]. Since IL-12 stimulates IFN-g
production, proliferation of T cells, and generation of
cytotoxic T lymphocytes, it is logical that LMP1 and
LMP1-CD40 result in increased DCs activation and a
strong TH1 immune response.
The chemokines MIP-1a,M I P - 1 b,a n dR A N T E Sp l a y
a critical role in innate immune control of HIV by DCs
and macrophages [28,29]. Surprisingly, LMP1 and
LMP1-CD40 were able to enhance these chemokines in
the context of recombinant SIV virus infection. How-
ever, LMP1 was unique in its ability to induce IL-12p70,
suggesting LMP1 would be a better inducer of T cell
responses. Again, this chemokine secretion highlights
the ability of LMP1 and LMP1-CD40 to increase the
immune response during SIV infection of DCs and
macrophages and suggests that these recombinant
viruses may block viral replication while simultaneously
enhances anti-HIV or SIV immune responses.
In addition to DC maturation and cytokine secretion,
the immunogenicity of LMP1 and LMP1-CD40 was
further confirmed by the coculture of virus infected DCs
with autologous T cells for 12 days. This datum suggests
that the LMP1 adjuvant gene cassette is able to convert
aw e a k l yi m m u n o g e n i cv i r u si n t oas t r o n g l yi m m u n o -
genic one that can augment T cell responses against
viral antigens. By comparison, scSIV-LMP1-CD40 was
less active in this assay, consistent with the overall
weaker effect of scSIV-LMP1-CD40 in DCs compared to
scSIV-LMP1 virus. This could reflect issues involved in
the protein engineering of LMP1-CD40 that inhibit opti-
mal CD40 signaling. Another explanation relates to the
unique character of the LMP1 signaling domain. LMP1
signaling induces B cell stimulation without the require-
ment for costimulation, while CD40 signaling is costi-
mulatory, needing additional signals for DC maturation
and activation. As such, LMP1-CD40 may require addi-
tional stimuli, such as TLR agonists, a possibility that is
currently being explored by our laboratory.
These data are encouraging, but it should be noted
that LMP1 and the LMP1-CD40 chimera tend to induce
qualitatively different responses on in terms of expres-
sion of surface markers and secretion of cytokines (Fig-
ures 3 and 4). Furthermore, the results obtained with
DCs and macrophages do not always correlate directly
(for example, compare CD40 and CD80 levels for Fig-
ures 3A to 3B). Despite these varied results, overall
LMP1 and LMP1-CD40 show promise as SIV-based vac-
cine adjuvants able to enhance DC and macrophage
immune responses.
While this approach is effective in inducing an
immune response, there are also safety issues related to
the use of LMP1. To improve the safety of this
approach, a number of options are available to shut off
LMP1 production in vivo. For example, the LMP1 and
LMP1-CD40 systems could be regulated using an indu-
cible promoter system [30,31]. Finally, the use of the
nonhuman protein LMP1 as a molecular adjuvant may
actually be advantageous compared to human-derived
molecular adjuvants such as CD40, for example, by low-
ering the risk of autoimmune responses.
Conclusions
O v e r a l l ,t h e s er e s u l t sp r o v i d et h ef i r s te v i d e n c et h a t
LMP1 can act as a potent molecular adjuvant, providing
a new class of adjuvant for use in recombinant vaccine
strategies. In addition, LMP1 and LMP1 chimeras could
be used as viral vector vaccine adjuvants or adjuvants
for DNA or RNA based vaccines. Use of LMP1 for
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being explored. These vaccines could potentially target
both DC and B cells, as B cell responses are also aug-
mented by LMP1 expression, including the induction of
T cell independent class switching [32].
Methods
Cells and media
Embryonic kidney (293T) cells were grown at 37°C
under 5% CO2 in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine, and antibiotics (100 U/ml
penicillin and 100 μg/ml streptomycin), (referred to as
complete medium). Human as well as rhesus macaque
peripheral blood mononuclear cells (PBMCs) were pre-
pared by Ficoll-Hypaque density centrifugation and
maintained in RPMI medium (Hyclone, Logan, UT) sup-
plemented with 5% human serum (Lonza, Allendale, NJ)
and 10 mM HEPES (Invitrogen, Carlsbad, CA).
Plasmid Construction
The construct SIVmac239 FS-ΔPR-ΔINEGFP (provided
by Dr. David Evans) contains mutations in the gag-pol
frameshift site (FS) and deletion in the protease (ΔPR)
integrase (ΔIN) coding regions of the pol gene. The Nef
coding region is replaced with GFP [33]. All constructs
with the immunostimulatory genes LMP1 or LMP1-
CD40 were cloned by overlap PCR and inserted into the
SIVmac239 FS-ΔPR-ΔINEGFP vector using unique XbaI
and SacII sites flanking the GFP gene. All viral clones
were confirmed by DNA sequencing both before and
after ligation into the viral vector. All DNA plasmids
were purified with the Qiagen Endo-Free kit and
checked for endotoxin levels prior to transfection.
Preparation of viral stocks
Single-cycle virus stocks were prepared by harvesting
the supernatant of 293T cells transfected with different
viral plasmids. VSV-G trans-complemented single-cycle
SIV was produced by co-transfection of 293T cells
with the Gag-Pol expression construct pGPfusion, 5 μg
of an expression construct for the Indiana or the New
Jersey serotype of VSV-G and a full-length proviral
DNA construct for each scSIV strain as previously
described [33-35]. 293T cells were seeded at 5 × 10
6
cell per 100-mm dish in cell culture medium (Dulbec-
co’s modified Eagle’s medium [DMEM] supplemented
with 10% fetal bovine serum [FBS], L-glutamine, peni-
cillin and streptomycin) and transfected the following
day with 5 μg of each plasmid using Genjet plus trans-
fection Reagent (Signagen Laboratories, Iamsville,
MD). Twenty-four hours after transfection, the plates
were rinsed twice with serum-free medium and the
cell culture medium was replaced with DMEM
supplemented with 10% FBS. Twenty-four hours later,
the cell culture supernatant was collected, clarified by
centrifugation at 500 × g for 10 min, and filtered
through a 0.45 μm-pore-size membrane (Millipore,
Bedford, MA). To prepare high-titre stocks, viral parti-
cles were concentrated by repeated low speed centrifu-
gation using YM-50 ultrafiltration units (Millipore,
Bedford, MA). Aliquots (1 mL) of scSIV were cryopre-
served at -80°C and the concentration of virus was
determined by p27 antigen capture ELISA (Advanced
BioScience Laboratories, Kensington, MD).
Single-cycle SIV infectivity assays
One million CEM×174 cells were incubated with 100 ng
p27 equivalents of scSIV in 100 μl volume for 2 hours
at 37°C. Cultures were then expanded to a volume of 2
ml in R10 medium (RPMI supplemented with 10% FBS,
L-glutamine, penicillin and streptomycin) and incubated
in 24-well plates at 37°C for 4 days. Cells were treated
with Fix and Perm reagents (BD Biosciences, San Jose,
CA) and stained with FITC-conjugated SIV Gag-specific
monoclonal antibody (Immunodiagnostics Inc. Woburn,
MA). After staining, cells were fixed in 2% paraformal-
dehyde PBS and analyzed by flow cytometry to deter-
mine the frequency of SIV Gag-positive infected cells.
Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and Western blotting
Viral particle stocks were run on a 10% sodium dode-
cyl sulfate-polyacrylamide gel (Bio-Rad, Hercules, CA).
Proteins were then transferred to nitrocellulose mem-
branes (0.22 μm; GE Osmonics, Minnetonka, MN) and
blocked (5% milk in PBS-0.2% Tween 20). The mem-
branes were incubated individually with primary anti-
body overnight at 4°C. These antibodies included the
following: (i) 1:100 dilution of mouse anti-EBV LMP1
monoclonal antibody (3H2104, a, b, c Santa Cruz Bio-
technology, Santa Cruz, CA), (ii) 1:500 dilution of
mouse anti-CD40 polyclonal antibody (C-20, Santa
Cruz Biotechnology, Santa Cruz, CA), and (iii) 1:2,000
dilution of mouse anti-Gag p27 antibody, obtained
through the National Institutes of Health AIDS
Research and Reference Reagent Program (German-
town, MD) (SIVmac251 Gag monoclonal [KK64], cata-
logue no. 2321, from Karen Kent and Caroline Powell).
Membranes were washed with PBS-0.2% Tween 20 and
incubated with horseradish peroxidase (HRP)-conju-
gated goat anti-mouse antibody (Pierce, Rockford, IL)
at a 1:5,000 dilution in blocking buffer. Following incu-
bation in the secondary antibody, the membranes were
washed and then incubated in HRP substrate (Pico
chemiluminescence; Pierce). Membranes were placed
on Whatman 3 MM filter paper and exposed to film
(BioMax; Kodak, Rochester, NY).
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macrophages and dendritic cells
PBMCs from healthy blood donors (Continental Blood
Services, Miami, FL) were isolated from buffy coats by
density centrifugation using Ficoll-Hypaque (Amersham
Pharmacia Biotech Inc., Piscataway, NJ). Cells were cul-
t u r e da t2×1 0
6 cells/ml, in RPMI-1640 media supple-
mented with 10% decomplemented human AB serum
(Biowhittaker, Walkersville, MD), 2 mmol/liter L-gluta-
mine, 100 U/ml penicillin G and 100 μg/ml streptomy-
cin (GIBCO BRL, Gaithersburg, MD), in a 5% CO2
atmosphere at 37°C. To isolate monocytes, PBMC
underwent plastic adherence on T175 tissue flasks
(Corning-Costar, Cambridge, MA). To generate enriched
populations of monocyte-derived macrophages (macro-
phages) and monocyte-derived dendritic cells (DCs) the
following procedures were performed. To generate
macrophages, adherent cells were extensively washed
and maintained for 24 h in medium supplemented with
10% heat-inactivated human serum. Adherent mono-
cytes were washed, removed from the flask by gentle
scraping, seeded onto 24-well plates at a density of 1 ×
10
6 cells/well, and cultured for seven days. To generate
immature DCs, plastic-adhered monocytes were cultured
in GM-CSF, 800 U/ml and IL-4, 500 U/ml (R&D Sys-
tems, Inc., Minneapolis, MN) for 5 days, adding fresh
GM-CSF and IL-4 on day 3. All cell culture reagents
were endotoxin free.
Virus transduction and flow cytometry
Immature DCs or macrophages were transduced at day
6. One million macrophages or DCs were incubated
with 50 ng p27 equivalents of scSIV (MOI of 0.05) in
100 μl volume for 2 hours at 37°C. Cultures were then
expanded to a volume of 2 ml in RPMI supplemented
with 5% human serum, L-glutamine, penicillin and
streptomycin and incubated at 37°C for 4 days. The cul-
ture supernatants of transduced macrophages or DCs
were collected at various time points and stored at -80°
C. Macrophages were stained on the plates, while DCs
were harvested by gently resuspending the cells and
staining with anti-CD40, anti-CD80, anti-CD83, anti-
CD86, anti-CD11c or anti-HLA-DR or anti-CCR7 in
fluorescence-activated cell sorter buffer (PBS supple-
mented with 3% fetal calf serum and 0.02% sodium
azide). Intracellular staining for p27 was also performed
to measure infectivity. Expression was monitored by
flow cytometric analysis using a LSRII bioanalyzer (Bec-
ton Dickinson) and analyzed using the FlowJo software
program (Tree Star, San Carlos, CA).
Chemokine and cytokine assays
Cell culture supernatants were obtained from macro-
phages and DCs infected with different viruses at
various time points. Supernatant samples were collected,
centrifuged for 5 min at 13,000 × g to clarify, and the
supernatant stored at -80°C. Concentrations of IL-1b,
IL-6, IL-8, IL-10, IL-12p70 and TNF were measured
using cytometric bead array (CBA) (BD Biosciences, San
Jose, CA) according to the manufacturer’s instructions.
RT-PCR analysis of chemokine mRNA
For the measurement of MIP-1a (CCL3), MIP-1b
(CCL4), and RANTES (CCL5) mRNA levels in the
infected macrophages and DCs, quantitative RT-PCR
was performed. Briefly, total RNA was prepared using
the RNeasy kit (Qiagen Inc., Valencia, CA), and reverse
transcribed in a 20 μl reaction containing 0.1 μg of total
RNA, 0.1 μg of oligo(dT), 200 U of reverse transcriptase
(Finnzymes, Finland) and 0.2 μM each of dATP, dCTP,
dGTP and dTTP. After 1 hr incubation at 40°C, cDNA
products were generated. Real-time PCR then was per-
formed using the Power SYBR Green Supermix (Applied
Biosystems) and the following primers: MIP-1a (CCL3)-
specific primers, 5-GTC TGT GCT GAT CCC AGT
GA-3 (forward) and 5-TTG TCA CCA GAC GCG GTG
TG-3(reverse); MIP-1b (CCL4)-specific primers, 5-GTC
TGT GCT GAT CCC AGT GA-3 (forward) and 5-GGA
CAC TTA TCC TTT GGC TA-3 (reverse); RANTES
(CCL5)-specific primers, 5-CCG CGG CAG CCC TCG
CTG TCA TCC-3 (forward) and 5-CAT CTC CAA
AGA GTT GAT GTA CTC C-3 (reverse). For normali-
zation, GAPDH and b-actin real-time PCR was carried
out on the same samples. Normalized mRNA levels for
each transcript were calculated as (1/2ΔCt × 1,000),
where ΔCt value = Ct (test mRNA) - Ct (GAPDH
mRNA). To control for contamination with genomic
DNA, parallel amplifications were performed in the
absence of reverse transcriptase. These were uniformly
negative.
ELISPOT assay
IFN-g ELISPOT assays were performed as previously
described [36]. Briefly, isolated PBMCs were plated at a
concentration of 100,000 cells per well in 96-well multi-
screen plates (Millipore, Bedford, MA) that had been
precoated with 0.5 g/ml of anti-IFN-g monoclonal anti-
body (BD Biosciences, San Jose, CA). An SIVmac239 Gag
peptide pool (15-mers overlapping by 11 aa (NIH AIDS
Reagent Program)) was added at a final concentration of
5 μg/ml. Four wells containing PBMCs and complete
medium alone were used as negative controls along with
four positive controls with Phorbol Myristate Acetate
(PMA, 5 ng/ml) and Ionomycin (500 ng/ml). Plates
were incubated overnight at 37°C, 5% CO2 and devel-
oped as described previously (11). The numbers of spots
per well were counted using an automated ELISPOT
plate reader (CTL technologies), and the number of
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tracting the negative-control wells (mean plus 3 stan-
dard deviations). A value of 55 SFC/10
6 PBMC or
greater (after subtraction of background) was considered
positive.
Statistics
Data were analyzed using PRISM 4.0 (GraphPad Soft-
ware, La Jolla, CA) and expressed as the mean ± SEM.
Statistical comparisons were analyzed by Student’s t test.
A p-value of 0.05 was chosen for statistical significance.
Additional material
Additional file 1: Calibrating infectivity and optimization of
multiplicity of infection (MOI) of scSIV. Fig. S1. To calculate the
optimal infection dose, CEM cells were infected with a range of ng/
million cells of VSV-G pseudotyped scSIV for 4 days and then stained
with FITC anti-p27 antibody and analyzed by flowcytometry. Optimal
infectivity was observed at 50 ng scSIV per million cells (MOI of 0.05).
Additional file 2: Table summarizing statistical analysis of cytokines
secretion data. Table S1. Statistical overview of cytokines secretion from
a representative experiment of infected human DCs and macrophages
(upper panel) and macaques DCs and macrophages (lower panel) with
LMP1 and LMP1-CD40 adjuvanted virus. Human inflammatory cytokine
quantitation was performed from the culture supernatants by cytometric
bead array (CBA). P values are shown for any statistically significant
differences between EGFP and LMP1/LMP1-CD40 viral constructs.
Abbreviations
DC: dendritic cell; SIV: simian Immunodeficiency virus; LMP1: latent
membrane protein 1; CBA: cytometric bead array
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